Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) Operating cash flow
Disc Medicine, Inc.'s operating cash flow for fiscal 2025 was −$180.4M, compared with −$93.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$197.5M. Over the past ten years it has ranged from −$180.4M (fiscal 2025) to −$27.5M (fiscal 2021) — the current reading is the lowest in ten years. Operating cash flow has fallen for 4 consecutive fiscal years. Disc Medicine, Inc. ranks 544th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$180.4M | — |
| FY2024 | −$93.9M | — |
| FY2023 | −$73.5M | — |
| FY2022 | −$42.3M | — |
| FY2021 | −$27.5M | — |
| FY2020 | −$32.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$44.2M | — |
| Mar 2026 | −$62.2M | — |
| Dec 2025 | −$43.3M | — |
| Sep 2025 | −$47.8M | — |
| 22 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $97.5M |
| PBLS Parabilis Medicines, Inc. compare | −$118.1M |
| TNGX Tango Therapeutics, Inc. compare | −$143.9M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$190.0M |
| IRON Disc Medicine, Inc. | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| XENE Xenon Pharmaceuticals Inc. compare | −$337.5M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$477.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item